Summary of Protagonist Therapeutics Conference Call Company Overview - **Company**: Protagonist Therapeutics (NasdaqGM:PTGX) - **Key Product**: ICOTYDE, an oral peptide-targeted therapy for moderate-to-severe plaque psoriasis Key Industry and Company Insights FDA Approval Announcement - Protagonist announced FDA approval of ICOTYDE for treating moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older who weigh at least 40 kg [2][4] - ICOTYDE is the first oral peptide-targeted therapy that blocks the IL-23 pathway by targeting the IL-23 receptor, contrasting with existing injectable antibodies that target the IL-23 ligand [4][6] Clinical Development and Efficacy - The approval was supported by a comprehensive phase 3 program involving approximately 2,500 patients across four studies, meeting all primary endpoints and demonstrating a favorable safety profile [7][9] - ICOTYDE has a broad label based on studies in both adults and adolescents, including head-to-head studies showing superiority to the active comparator, Sotyktu [8] Financial Implications - The approval triggers a $50 million milestone payment from Johnson & Johnson (J&J) and initiates a royalty-based revenue stream [10] - Protagonist has earned a total of $387 million in milestone payments since the collaboration with J&J began in 2017, with an additional $580 million in potential future milestones [10][11] - The royalty structure includes tiered royalties ranging from 6% to 10% on global net sales, with a weighted average of 7.25% at $4 billion in annual sales [12] Strategic Partnerships - Protagonist emphasizes the importance of its collaboration with J&J, which is responsible for commercialization and ongoing clinical trials of ICOTYDE [13] - The partnership has been described as a win-win, highlighting the potential blockbuster category of ICOTYDE [13] Pipeline and Future Developments Additional Assets - Protagonist is expecting FDA approval for rusfertide, a hepcidin mimetic for polycythemia vera, in the third quarter of the year [14][15] - The company is developing new R&D assets, including an oral IL-17 peptide antagonist (PN881) and an oral triple GLP GIP GCG agonist (PN477) for obesity [16][17] Financial Position and Shareholder Value - Protagonist aims to fund its R&D programs without equity offerings, focusing on returning capital to shareholders through potential share buybacks [19][20] - The company is exploring partnerships for its IL-17 and obesity programs, with ongoing dialogues with multiple parties [107] Market Position and Competitive Landscape - Protagonist believes ICOTYDE can capture market share from existing injectables and attract patients currently not on treatment due to aversion to injections [53][54] - The company is focused on differentiating its products in a competitive landscape, particularly in the obesity space where unmet needs exist [77][96] Conclusion - The approval of ICOTYDE marks a significant milestone for Protagonist, validating its peptide technology platform and setting the stage for future growth and product-driven cycles [20][22] - The company is well-positioned financially and strategically to expand its pipeline and enhance shareholder value through innovative therapies and partnerships.

Summary of Minerva Neurosciences Conference Call Company Overview - **Company**: Minerva Neurosciences (NasdaqCM:NERV) - **Focus**: Development of roluperidone, a potential treatment for schizophrenia, specifically targeting negative symptoms [1][2] Industry Context - **Schizophrenia Symptoms**: Schizophrenia is characterized by three types of symptoms: positive, negative, and cognitive deficits. Negative symptoms significantly impair quality of life and are currently not effectively treated by existing antipsychotics [2][3][4] - **Negative Symptoms**: These include avolition (lack of motivation), which is crucial for patient functioning and quality of life. Current treatments do not address these symptoms adequately, leading to a significant unmet medical need [5][6][7] Core Points and Arguments - **Treatment Gap**: There is no approved treatment for negative symptoms of schizophrenia in the U.S. as of now, and existing antipsychotics may worsen these symptoms [4][5] - **Clinical Trial Design**: The company emphasizes the need for innovative trial designs to assess the efficacy of treatments for negative symptoms, suggesting that traditional methods may not be suitable [8][9] - **Pharmacology of Roluperidone**: Roluperidone works through mechanisms that do not block dopamine, which is believed to help maintain stability in positive symptoms while improving negative symptoms [16][17] - **Efficacy Data**: In clinical trials, roluperidone showed significant improvements in negative symptoms and functioning, with a low relapse rate when used as monotherapy. The drug was well-tolerated with no significant side effects [22][24][23] Important Data Points - **Clinical Trial Results**: - The primary endpoint was assessed using the PANSS scale, with significant improvements noted at week 12. The 64 mg dose showed stronger effects compared to the 32 mg dose [19][20] - The first study had a p-value of 0.0001, indicating strong efficacy, while the second study showed a nominal improvement for the 64 mg dose [20][21] - **Patient Population**: Over 800 patients participated in the trials, with a focus on those with stable positive symptoms and significant negative symptoms [17] Regulatory Considerations - **FDA Interactions**: The company has engaged in discussions with the FDA regarding trial design and endpoints, aiming to establish a clear path for approval given the lack of existing treatments for negative symptoms [25][26] - **Study Design**: The upcoming study will compare roluperidone to commonly prescribed antipsychotics, using a double-dummy design to maintain blinding [28] Future Outlook - **Timeline for Results**: The first patient in the new study is expected to be enrolled in Q2 of the current year, with top-line results anticipated in the second half of next year [41][42] - **Regulatory Submission**: Following the results, the company plans to re-engage with the FDA regarding NDA submission [42] Additional Considerations - **Clinical Meaningfulness**: The company is working to establish clinically meaningful effect sizes in collaboration with the FDA, given the absence of approved treatments for negative symptoms [30][31] - **Relapse Assessment**: The study will include psychometric endpoints and hard clinical endpoints to assess relapse rates and overall patient safety [39][40]

New Fortress Energy (NFE) Conference Call Summary Company Overview - **Company**: New Fortress Energy (NFE) - **Date of Call**: March 18, 2026 - **Key Event**: Announcement of a significant debt-for-equity exchange transaction Core Points and Arguments 1. **Transaction Overview**: NFE completed a debt-for-equity exchange, which is one of the largest consensual restructurings ever completed, supported by major creditors and expected to be approved by shareholders [3][5] 2. **UK Restructuring Plan (UKRP)**: The transaction utilized a UKRP process allowing the exchange of debt for equity while maintaining uninterrupted operations and customer service [4][6] 3. **Debt Reduction**: NFE's corporate debt will be reduced from approximately $5.7 billion to about $527 million, representing a reduction of over 90% [6][10] 4. **Equity Structure Post-Transaction**: Existing shareholders will own 35% of the new NFE after the transaction, with significant dilution from the issuance of new shares [8][10] 5. **Separation of Entities**: The old NFE will be split into two entities: BrazilCo (a private company) and the new NFE, which will continue as a publicly traded integrated LNG to power company [6][10] 6. **Capital Structure**: The new capital structure includes $527 million in corporate debt and $2.5 billion in preferred equity, with a simplified and stronger balance sheet [11][12] 7. **Cash Flow Profile**: The company anticipates significant cash flow from its operations, with a target leverage of 2-3 times EBITDA, consistent with investment-grade issuers [11][12] 8. **Operational Stability**: The restructuring is expected to enhance operational stability and growth potential, particularly in light of current energy market conditions [17][19] Additional Important Content 1. **Stakeholder Engagement**: The company emphasized the importance of collaboration with employees, customers, vendors, and creditors to achieve a successful outcome without resorting to bankruptcy [20][21] 2. **Cost Reductions**: NFE has reduced operational expenses by $55 million for 2026, $70 million for 2027, and over $200 million cumulatively in 2028 and beyond [23][24] 3. **Future Growth Initiatives**: Key initiatives include the completion of the Nicaragua terminal, gas conversion projects in Puerto Rico, and deployment of turbine assets to enhance cash flow [35][50] 4. **Earnings Projections**: NFE projects adjusted EBITDA of over $400 million for 2027, with potential for significant incremental EBITDA from additional gas supply contracts [42][43] 5. **Liquidity Position**: The company ended the year with $225 million in unrestricted cash and has a minimum liquidity requirement of $100 million, ensuring financial stability post-restructuring [46] Conclusion - The restructuring positions NFE for a stable and growth-oriented future, with a focus on matching supply and demand in the LNG market while maintaining operational integrity and financial health [52][53]

Vertiv (NYSE: VRT) 2026 Conference Summary Industry Overview - The discussion revolves around the data center infrastructure industry, particularly focusing on AI and cooling technologies, as well as the impact of geopolitical situations on supply chains and market dynamics [1][2]. Key Points and Arguments Market Resilience and Geopolitical Impact - Vertiv operates in the EMEA market, including the Middle East, and has built supply chain resilience over the years. The actual impact of geopolitical situations is still uncertain, but there is confidence in market resilience [2]. Demand for AI and Technological Evolution - There is a significant demand for AI technologies, confirmed by both NVIDIA and Vertiv. The evolution of silicon and IT systems is crucial, leading to more cost-efficient AI operations [6][7]. - Vertiv is involved in NVIDIA's Omniverse DSX infrastructure, aimed at optimizing data center designs and deployments [7][8]. Prefabrication and Integrated Infrastructure - The company sees opportunities in prefabrication and integrated infrastructure, which can increase value and capture more market share. The focus is on delivering tailored systems that optimize performance [15][20]. Industry Growth and Adoption of AI - The industry is still in the early stages of AI adoption, with a long growth trajectory ahead. There is strong demand, and the company does not foresee any immediate risks or air pockets in the market [25][36]. Bottlenecks and Challenges - Power supply remains a key bottleneck, but it is being managed effectively. Labor and construction complexities are also challenges, which prefabrication aims to alleviate [31][35]. Customer Selection and Long-term Relationships - Vertiv is selective in choosing projects and focuses on long-term relationships with customers to ensure stability and ongoing revenue from services [48][49]. Cooling Technologies - Liquid cooling is becoming ubiquitous, with a shift from air cooling. The company is adapting its systems to be more efficient and effective, depending on geographical and climatic conditions [91][96]. Services and Lifecycle Management - The complexity of new cooling systems creates opportunities for service growth. The company is focused on lifecycle services, which are expected to grow steadily as equipment comes off warranty [115][122]. Financial Performance and Margins - The company aims for a gross margin of 30%-35% in the long term, with current margins impacted by investments and tariffs. There is a focus on optimizing productivity and managing raw material costs [142][145]. Cash Management and Strategic Investments - Vertiv maintains a strong balance sheet and is cautious about spending. The focus is on R&D and CapEx for immediate returns, rather than stock buybacks or dividends [163][164]. Future Outlook - The company anticipates continued growth in both the cooling and power markets, with synchronous growth rates expected. The enterprise market is also showing signs of growth, particularly in private data and AI applications [102][107][110]. Additional Important Insights - The company emphasizes the importance of being server agnostic in its thermal infrastructure strategy, allowing flexibility in serving various server types [167]. - The transition to 800-volt DC technology is seen as a significant change, with confidence in its future coexistence with traditional powertrain designs [70][168]. This summary encapsulates the key discussions and insights from the Vertiv conference, highlighting the company's strategic focus, market dynamics, and future growth opportunities.

Summary of Air Products and Chemicals Conference Call Company Overview - **Company**: Air Products and Chemicals (NYSE: APD) - **CEO**: Eduardo Menezes, with a background at Linde and Praxair - **CFO**: Melissa Schaeffer - **Industry**: Chemicals, specifically industrial gases Key Points Impact of Regional Conflicts - The ongoing conflict in Iran has created a hectic environment for Air Products, particularly affecting operations in the Middle East, where the company has a significant presence [2][3] - Operations include 100% owned facilities in Saudi Arabia, Oman, Qatar, UAE, Bahrain, Egypt, and Israel, as well as joint ventures in Saudi Arabia [2][3] - Main concern is the safety of employees and assets, with minimal direct impacts on business aside from minor plant closures [4] Energy Prices and Inflation - Energy prices in Europe have surged, with natural gas prices rising from $15 to $18 per MMBtu due to the conflict [6][12] - Air Products has mechanisms in place to pass through energy cost increases to customers, particularly in hydrogen and air separation businesses [10][13] - The company is monitoring the situation closely to manage inflationary pressures on operations [6][12] Helium Market Dynamics - The helium market has become more volatile, particularly due to the closure of QatarEnergy's LNG operations, which affects global helium supply [5][20] - Air Products has its own helium production and storage strategies, including caverns in Texas, but does not control the entire market supply [20][50] - Helium prices have reportedly increased by 20% to 40% since the conflict began, although Air Products' long-term contracts mitigate immediate impacts [60][67] NEOM Project Update - The NEOM project, focused on renewable energy and hydrogen production, has not been significantly affected by the conflict, although travel restrictions pose challenges [102][104] - Construction is progressing well, with power generation sites nearing completion and commissioning of the air separation plant underway [105][106] - Expected production capacity is around 1.1 million tons of ammonia, with plans to sell at a premium compared to gray ammonia prices [110][118] Market Outlook and Pricing - Air Products has seen strong volume growth in the Americas, particularly in the HyCO business, despite broader market uncertainties [75][86] - Non-helium pricing has remained strong in the Americas and Europe, while Asia has seen flat pricing [90][92] - The company anticipates potential improvements in helium contract renewals due to current market conditions [93][98] Strategic Partnerships - Air Products is engaged in strategic partnerships, such as with Yara, to enhance hydrogen production capabilities and project feasibility [141][143] - The focus is on long-term collaboration rather than short-term gains, with ongoing assessments of project viability [143][145] Additional Insights - The company is committed to maximizing shareholder value and adapting to market conditions, including potential shifts in ammonia and hydrogen demand [136][138] - Air Products is positioned well for long-term success in the renewable energy sector, particularly with its NEOM project and strategic partnerships [122][123]

Summary of Canadian Pacific Kansas City (CPKC) Conference Call Company Overview - **Company**: Canadian Pacific Kansas City (NYSE: CP) - **Date**: March 18, 2026 - **Participants**: President and CEO Keith Creel, VP of IR Maeghan Albiston Key Points Industry Performance and Company Strategy - CPKC has maintained operational momentum into 2026, focusing on improving terminal dwell, network fluidity, and cost control [6][8] - The company has successfully integrated operations and created differentiated results despite macroeconomic challenges [7] - CPKC is strategically positioned to connect Canada, Mexico, and the U.S., leveraging its network for growth [7] Financial Performance - The first quarter of 2026 is expected to be challenging due to comparisons with last year's performance, but CPKC anticipates growth and is on track to meet full-year guidance [8] - Fuel prices have increased, impacting earnings by approximately CAD 0.04, but surcharges are expected to mitigate this in the next quarter [10] Market Dynamics - The ongoing conflict in the Middle East is not expected to have a long-term impact on CPKC's operations, although there are concerns about bunker fuel availability [14] - CPKC has a strong relationship with Hapag-Lloyd, which is pursuing an acquisition of Zim; this is expected to be beneficial for CPKC as it will increase traffic through its network [16][17] Trade Relationships and Opportunities - CPKC is optimistic about the USMCA renegotiations, believing that a good relationship between the U.S. and Mexico will enhance trade opportunities [19][20] - The company is seeing increased traffic through Lázaro Cárdenas, with a 15% growth rate last year, indicating a recovery in reliability and trust in the supply chain [25] Infrastructure and Service Enhancements - CPKC is investing in infrastructure to improve service reliability, including a new service from Atlanta to Monterrey that will significantly reduce transit times [28] - The company is focused on converting truckloads to rail, with a target of removing 64,000 trucks from the road annually, currently at 40% of that goal [72][73] Regulatory Environment - The STB's recent ruling on the Meridian Speedway is seen as a positive outcome for CPKC, affirming its operational strategy and clarifying the importance of factual evidence in regulatory decisions [48][54] - Concerns about potential mergers in the industry, particularly between UP and NS, are highlighted, with CPKC advocating for careful consideration of competition and market balance [62][66] Future Outlook - CPKC anticipates continued growth in cross-border trade, with traffic between Mexico and Canada increasing from 2% to over 3% of revenue, contributing nearly half a billion dollars in new revenue over the past two years [80] - The company is optimistic about diversifying markets and expanding its service offerings, particularly in light of recent trade uncertainties [79] Additional Insights - CPKC emphasizes the importance of reliability and security in its operations, particularly in regions affected by political and cartel-related violence, which has not significantly impacted its core network [31][34] - The company is exploring further co-location opportunities with partners like Americold to enhance service offerings and operational efficiency [45][46] This summary encapsulates the key insights and strategic directions discussed during the conference call, reflecting CPKC's commitment to growth and operational excellence in the rail industry.

Morgan Stanley (NYSE:MS) 2026 Conference March 18, 2026 07:00 AM ET Company ParticipantsAlvaro Serrano - Head of European Banks Equity ResearchDan Simkowitz - Co-President and Head of Institutional SecuritiesAlvaro SerranoThanks everyone for coming to this session with our very own Dan Simkowitz, Co-President of Morgan Stanley. Thanks, Dan, for supporting us.Dan SimkowitzThank you.Alvaro Serrano... one more year. Before we get started, I'm gonna read the disclaimer. The discussions may include forward-looki ...

Summary of Parker Hannifin Conference Call Company Overview - **Company**: Parker Hannifin - **CEO**: Jennifer Parmentier - **Business Segments**: - Aerospace Systems: 31% - Diversified Industrial International: ~30% - Diversified Industrial North America: ~40% [2][5] Core Business Insights - **Technology Platforms**: Four main platforms include Motion Systems (17%), Aerospace (31%), Flow and Process Control (23%), and Filtration and Engineered Materials (~30%) [3] - **Win Strategy**: A guide to operational excellence that emphasizes decentralized decision-making with 85 general managers who are P&L owners [4][3] - **Market Position**: Number one in the motion and control industry with projected sales of approximately $21 billion [5] Financial Performance - **Revenue Growth**: 6% CAGR over the last 10 years, with 1,150 basis points of adjusted operating margin expansion and 16% EPS CAGR [6] - **Acquisitions Impact**: 60% of EPS performance from legacy businesses, 40% from acquisitions like LORD, CLARCOR, Exotic, Meggitt, and Curtis [7] Market Dynamics - **Aerospace Growth**: Fourth consecutive year of double-digit growth, with a strong focus on commercial OEM [16] - **Industrial Recovery**: Gradual recovery noted, with organic growth increasing from 3% to 5% for total Parker and from 2%-2.5% for North America [17][19] - **Positive Distributor Sentiment**: Strong quoting activity and inventory management observed [16] Pricing and Cost Environment - **Pricing Strategy**: Strong pricing capabilities to manage tariffs and inflation without impacting margins [21] - **Distribution Channel**: Normal pricing environment has returned after hyperinflationary periods, with no significant pushback reported [21] Acquisition Strategy - **Filtration Group Acquisition**: Expected to close within 6-12 months, targeting 11% synergies due to the integration of existing Parker divisions [132][141] - **Curtis Acquisition**: Positive impact on EPS, initially dilutive to margins but on track for financial goals [43][44] Macro Environment - **Geopolitical Concerns**: Safety of team members prioritized amid geopolitical tensions, with a positive outlook on the defense business [11][12] - **Market Conditions**: Uncertainty around tariffs and interest rates affecting customer decisions [62] International Business - **Growth in International Markets**: Positive orders for six consecutive quarters, with strong performance in Europe and Asia-Pacific [88][90] - **China and India**: Notable growth in China driven by automotive and electronics, with a strong manufacturing presence in India [92][93] Future Outlook - **Gradual Recovery**: Anticipated smooth operational ramp-up with a focus on customer demand and supply chain visibility [94] - **Continued M&A Activity**: Ongoing evaluation of potential acquisitions that align with Parker's strategic goals [161][165] Additional Insights - **Life Sciences Market**: Increased focus on biopharma reshoring and diagnostic testing post-Filtration Group acquisition [121][122] - **Energy Sector**: 7% of total sales from energy, with a robust backlog in power generation [80][84] This summary encapsulates the key points discussed during the Parker Hannifin conference call, highlighting the company's strategic direction, financial performance, market dynamics, and future outlook.

Summary of Standard Chartered Conference Call Company Overview - **Company**: Standard Chartered (SEHK: 02888) - **Date**: March 18, 2026 - **Speaker**: Peter Burrill, Interim CFO Key Points Financial Performance and Targets - **2025 Results**: Exceeded targets with underlying Return on Tangible Equity (ROTE) of 14.7%, surpassing the 13% target [7] - **2026 Targets**: Aiming for over 12% ROTE, mid-single digit income growth, and broadly flat costs [7] - **Q1 Performance**: Strong start in wealth management with continued growth in net new money [8] Revenue Opportunities - **Wealth Management Growth**: Achieved net new money growth of $52 billion, representing 14% of Assets Under Management (AUM) [21] - **Investment in Wealth Management**: Committed $1.5 billion to enhance wealth management capabilities, including technology and real estate [21] - **Competitive Position**: Standard Chartered is the third largest wealth manager in Asia, growing faster than competitors [20] Risk Management and Credit Quality - **Credit Quality**: Over 80% of corporate investment banking (CIB) operations in the Middle East are investment grade, with no immediate concerns [11] - **Mortgage Portfolio**: UAE mortgage portfolio has a Loan-to-Value ratio below 50%, conservatively underwritten [47] Cost Management - **Cost Discipline**: Achieved 4% positive jaws in 2025, with ongoing focus on productivity and cost management [34] - **Fit for Growth Program**: Continues to drive efficiency and productivity improvements [38] Capital Management - **Capital Return Strategy**: Increased dividend by 65% and announced a $1.5 billion share buyback [41] - **Capital Allocation**: Prioritizing capital for business growth while maintaining sustainable dividends [43] Market and Economic Outlook - **Trade and Geopolitical Risks**: Belief that global trade will continue despite geopolitical challenges; strong network positions the company well [29] - **Market Volatility**: Acknowledgment of potential impacts from oil prices, inflation, and interest rates on business performance [12] Technology and Innovation - **AI Adoption**: Early stages of AI integration, primarily enhancing productivity in wealth management [72] - **Digital Assets**: Active in digital asset space, including plans for a stablecoin license in Hong Kong [61] Future Considerations - **Tokenization and Digital Currencies**: Exploring opportunities in tokenized deposits and stablecoins, with a focus on regulatory compliance [62][68] - **Long-term Strategy**: Emphasis on maintaining a diverse portfolio and cautious approach to new market opportunities [17] Additional Insights - **Wealth Management Strategy**: Focus on affluent and cross-border clients, leveraging brand presence in key markets like Hong Kong and Singapore [24] - **Corporate Banking**: Strong belief in the resilience of trade flows and the ability to adapt to changing market conditions [30] - **Digital Banking Integration**: Merging digital banks into the main business units to enhance service offerings and operational efficiency [75] This summary encapsulates the key insights and strategic directions discussed during the Standard Chartered conference call, highlighting the company's performance, growth opportunities, risk management, and future outlook.

Summary of Rockwell's Conference Call Company Overview - Rockwell Automation reported over $8 billion in sales last year, with a significant concentration in North America, which is expected to be the fastest-growing market by 2026 [2][3] - The company has three reportable segments: Intelligent Devices ($3.7 billion), Software & Control ($2.4 billion), and Lifecycle Services [3] Core Growth Strategies - Rockwell initiated a long-term growth algorithm targeting GDP plus growth, with expectations of 3%-5% share growth and a focus on acquisitions to expand market presence [3][4] - Annual Recurring Revenue (ARR) constitutes about 10% of the business, projected to grow at a high single-digit rate, contributing to overall growth [4][5] - The company aims for a total company margin target of 23.5%, with a current guide of 21.5% for the year [9][10] Operational Excellence and Margin Expansion - Rockwell expanded operating margins by 110 basis points last year and aims to achieve similar results this year [7][8] - Lifecycle Services is already within the margin target corridor of 13%-15%, while Intelligent Devices is working towards a target of 22%-24% [8] - The company has focused on productivity improvements, including a $2 billion investment cycle over five years to enhance operational efficiency [10][69] Market and Economic Outlook - The macroeconomic environment shows positive indicators, but uncertainty remains, particularly regarding trade and geopolitical stability [20][21] - The company experienced double-digit top-line growth in Q1, but the outlook for the second half appears more muted due to conservative guidance [21][25] Software and AI Capabilities - Rockwell's software capabilities are integrated with hardware, focusing on machine control and operational efficiency [32][33] - The company sees AI as a significant opportunity to enhance intelligent machine capabilities and optimize production processes [42][46] Lifecycle Services and ARR Trends - The ARR is balanced between software and services, with a focus on supporting customers amid a skilled labor shortage [53][55] - Recent quarters have shown slower growth in ARR, particularly in services, but software ARR is growing above the overall rate [55][58] Manufacturing and Investment Strategy - Rockwell is transitioning to a more asset-intensive organization, with investments in automation and new facilities in Singapore, Twinsburg, and a planned greenfield facility in Wisconsin [96][98] - The company aims to demonstrate world-class manufacturing capabilities in higher-cost locations [101] End Market Exposure - Life sciences are a key growth vertical, with Rockwell well-positioned to support personalized medicine and modular manufacturing [107][109] - E-commerce and warehouse automation have seen significant growth, with a 60% increase in Q1, driven by investments in automation and fulfillment centers [113][121] Conclusion - Rockwell Automation is focused on achieving profitable growth through operational excellence, strategic investments, and leveraging its software capabilities to meet evolving market demands. The company remains optimistic about its growth prospects despite macroeconomic uncertainties.